Managment of Relapsed/Refractory ALL With Inotuzumab During COVID-19. A Casr Report

Main Article Content

Martina Di Palma
Elio Gentilini
Chiara Masucci
Alessandra Micozzi
Ombretta Turriziani
Antonino Mulè
Robin Foà
Maurizio Martelli
Gabriella D'Ettorre
Saveria Capria
Sabina Chiaretti


acute lymphoblastic leukemia, COVID-19, inotuzumab, remdesevir, convalescent plasma


Management of patients with concomitant acute lymphoblastic leukemia (ALL) and COVID-19 infection is challenging. We describe the clinical history of a 40-year-old male with relapsed B-common ALL who developed Sars-CoV2 prior to treatment initiation with inotuzumab. Since the patient was asymptomatic for COVID-19, the first dose of inotuzumab was administered, followed by remdesivir as prophylaxis. However, a worsening in respiratory findings led to a delay in administering the following doses of inotuzumab. Interestingly, even if the patient did not receive the full inotuzumab cycle, he achieved a complete hematologic remission: furthermore, he spontaneously developed anti-sars-COV2 antibodies. COVID-19 treatment also included convalescent plasma, leading to negativization of the viral load. The patient, after COVID-19 recovery, received a second full cycle of inotuzumab, underwent allogeneic transplantation, and is currently in complete hematologic and molecular remission, in good clinical conditions, five months from allograft.

Keywords: acute lymphoblastic leukemia, COVID-19, inotuzumab, remdesevir, convalescent plasma


Download data is not yet available.

Abstract 818
PDF Downloads 387
HTML Downloads 138